Business
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Co
About this update from Intelligent Bio Solutions Inc.
[{"type":"image","alt":"Intelligent Bio Solutions, Inc.","displaySize":"","headline":null,"caption":"Intelligent Bio Solutions, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":53,"url":"https://media.zenfs.com/en/globenewswire.com/9eadf03086af52dd7cf59a7dde9f27c4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dyf1dhe.u4apapwa.JaM4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9eadf03086af52dd7cf59a7dde9f27c4","width":300,"height":53},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dyf1dhe.u4apapwa.JaM4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/9eadf03086af52dd7cf59a7dde9f27c4","width":300,"height":53}},"lazy":false},{"type":"text","content":"Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales","length":129,"tagName":"p"},{"type":"text","content":"Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance","length":106,"tagName":"p"},{"type":"text","content":"Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period","length":155,"tagName":"p"},{"type":"text","content":"NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update.","length":391,"tagName":"p"},{"type":"text","content":""The third quarter marked another period of strong commercial execution and revenue growth," said Harry Simeonidis, President and CEO at INBS. "Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar...